Brookline Capital Management boosted their FY2024 earnings per share estimates for CRISPR Therapeutics in a research note issued on Monday, January 6th. Brookline Capital Management analyst L. Cann ...
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you ...
We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where ...
Nordea Investment Management AB grew its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 4.4% in the ...
BofA analyst Alec Stranahan lowered the firm’s price target on Crispr Therapeutics (CRSP) to $85 from $98 and keeps a Buy rating on the shares.
Check the time stamp on this data. Updated AI-Generated Signals for Crispr Therapeutics Ag (CRSP) available here: CRSP.
NEW YORK & CHICAGO, January 09, 2025--(BUSINESS WIRE)--OptionMetrics, an options database and analytics provider for institutional investors and academic researchers worldwide, and CRSP ...
Bullish option flow detected in Crispr Therapeutics (CRSP) with 3,137 calls trading, 1.3x expected, and implied vol increasing almost 2 points ...
High-rolling investors have positioned themselves bullish on CRISPR Therapeutics (NASDAQ:CRSP), and it's important for retail traders to take note. \This activity came to our attention today ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback